» Articles » PMID: 16049320

Establishment of a Diabetic Mouse Model with Progressive Diabetic Nephropathy

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2005 Jul 29
PMID 16049320
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Although diabetic animal models exist, no single animal model develops renal changes identical to those seen in humans. Here we show that transgenic mice that overexpress inducible cAMP early repressor (ICER Igamma) in pancreatic beta cells are a good model to study the pathogenesis of diabetic nephropathy. Although ICER Igamma transgenic mice exhibit extremely high blood glucose levels throughout their lives, they survive long enough to develop diabetic nephropathy. Using this model we followed the progress of diabetic renal changes compared to those seen in humans. By 8 weeks of age, the glomerular filtration rate (GFR) was already increased, and glomerular hypertrophy was prominent. At 20 weeks, GFR reached its peak, and urine albumin excretion rate was elevated. Finally, at 40 weeks, diffuse glomerular sclerotic lesions were prominently accompanied by increased expression of collagen type IV and laminin and reduced expression of matrix metalloproteinase-2. Nodular lesions were absent, but glomerular basement membrane thickening was prominent. At this point, GFR declined and urinary albumin excretion rate increased, causing a nephrotic state with lower serum albumin and higher serum total cholesterol. Thus, similar to human diabetic nephropathy, ICER Igamma transgenic mice exhibit a stable and progressive phenotype of diabetic kidney disease due solely to chronic hyperglycemia without other modulating factors.

Citing Articles

Differentiation, reduction, and proliferation of pancreatic β-cells and their regulatory factors.

Inada A Diabetol Int. 2025; 16(1):23-29.

PMID: 39877437 PMC: 11769892. DOI: 10.1007/s13340-024-00774-x.


Differences in long-term effects of standard rodent diets on blood glucose and body weight of offspring.

Inada A, Inada O Diabetol Int. 2022; 13(4):615-623.

PMID: 36117929 PMC: 9477981. DOI: 10.1007/s13340-022-00578-x.


The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Cabral-Pacheco G, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuna J, Perez-Romero B, Guerrero-Rodriguez J Int J Mol Sci. 2021; 21(24).

PMID: 33419373 PMC: 7767220. DOI: 10.3390/ijms21249739.


Matrix Metalloproteinases in Diabetic Kidney Disease.

Garcia-Fernandez N, Jacobs-Cacha C, Mora-Gutierrez J, Vergara A, Orbe J, Soler M J Clin Med. 2020; 9(2).

PMID: 32046355 PMC: 7073625. DOI: 10.3390/jcm9020472.


Adjusting the 17β-Estradiol-to-Androgen Ratio Ameliorates Diabetic Nephropathy.

Inada A, Inada O, Fujii N, Nagafuchi S, Katsuta H, Yasunami Y J Am Soc Nephrol. 2016; 27(10):3035-3050.

PMID: 26940099 PMC: 5042662. DOI: 10.1681/ASN.2015070741.


References
1.
Zatz R, Meyer T, Rennke H, Brenner B . Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A. 1985; 82(17):5963-7. PMC: 390674. DOI: 10.1073/pnas.82.17.5963. View

2.
Inada A, Weir G, Bonner-Weir S . Induced ICER Igamma down-regulates cyclin A expression and cell proliferation in insulin-producing beta cells. Biochem Biophys Res Commun. 2005; 329(3):925-9. DOI: 10.1016/j.bbrc.2005.02.046. View

3.
Krolewski A, Warram J, Rand L, Kahn C . Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med. 1987; 317(22):1390-8. DOI: 10.1056/NEJM198711263172206. View

4.
Tochino Y . The NOD mouse as a model of type I diabetes. Crit Rev Immunol. 1987; 8(1):49-81. View

5.
Velasquez M, Kimmel P, Michaelis 4th O . Animal models of spontaneous diabetic kidney disease. FASEB J. 1990; 4(11):2850-9. DOI: 10.1096/fasebj.4.11.2199283. View